Utah allows Nolla Health to offer AI acne exams and prescriptions
Utah is becoming the first state to allow a healthcare startup to offer AI examinations and prescriptions to patients without direct human oversight. The program changes how artificial intelligence is deployed within regulated clinical environments, moving digital health tools from advisory search features into direct diagnostic and prescribing roles.
How Nolla Health Automates Acne Examinations and Prescriptions in Utah
The pilot initiative operates through a subscription service created by healthcare startup Nolla Health. Patients subscribe to the mobile application for $4.99 per month, complete an intake form detailing their personal medical history, and upload a facial scan. The software evaluates the imagery to identify skin conditions, assess oiliness levels, and assign a numerical severity score ranging from clear skin to severe acne.
Following the assessment, the application cross-references the severity score with patient intake data to select a treatment plan from a roster of eight approved medications. To manage safety risks during the rollout, the program applies a phased oversight structure. The initial 100 prescriptions require direct review by licensed medical professionals before submission to a pharmacy. The subsequent 400 prescriptions shift to automated submission with retrospective physician reviews conducted on a weekly basis. In the final phase, supervising doctors will audit a minimum of 10 percent of all issued prescriptions once a month.
Safety Guardrails and the Debate Over Automated Prescribing
Nolla Health Chief Executive Officer Luis Wenus noted that the risks associated with the current Utah rollout are minimized because the eight approved treatments are restricted to topical formulations rather than systemic pills. Adverse effects are confined primarily to localized skin dryness or irritation. While the current scope remains restricted strictly to mild-to-moderate acne over a one-year trial period, the deployment establishes a regulatory precedent for autonomous medical treatment.
Nolla Health Trials Acne Diagnostics over Twelve Months
The state-level rollout is intentionally narrow to test automated diagnostics under controlled real-world conditions. Regulatory clearance applies exclusively to the Nolla Health platform for the treatment of acne over its twelve-month trial window. Patients experiencing severe dermatological symptoms or conditions outside the designated scope must seek traditional clinical evaluation through dermatology practices and healthcare clinics.